Today: 28 June 2026
Browse Category

TSX:4519 8 July 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Tokyo Stock Exchange Surges to Record Highs on AI Boom – Inside the Nov 3, 2025 Rally

Japan Stocks Today: Topix Closes at Record 3,359 as Nikkei Ends at 51,063; Sony’s Upgrade Offsets SoftBank Slump, Yen Nears ¥155

Topix closed at a record 3,359.33, up 1.14%, while the Nikkei 225 rose 0.43% to 51,063.31. SoftBank fell after confirming a $5.8 billion sale of its Nvidia stake; Sony jumped on an 8% profit forecast hike. The yen weakened near ¥155 per dollar. About 78% of Prime market stocks advanced.
12 November 2025
········
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

More than 777 FDA-cleared AI devices are in clinical use for medical imaging in the U.S., cutting scan times and flagging urgent cases. Microsoft's MAI-DxO system reached 85.5% diagnostic accuracy, far above doctors at 20%. The U.S. Senate rejected a 10-year moratorium on state AI regulation. Meta recruited Apple’s Ruoming Pang for its AI push, while Wimbledon 2025 adopted AI-driven line calling amid player criticism.
8 July 2025
······

Stock Market Today

  • Cathie Wood's ARK Invest Buys SpaceX Shares Amid 23% Price Drop After Historic IPO
    June 28, 2026, 2:35 PM EDT. After SpaceX's historic IPO on June 12, 2026, shares fell over 23% in days. Cathie Wood's ARK Invest seized the dip, investing more than $30 million on June 22 to add over 210,000 shares, on top of $400 million spent at IPO pricing. Wood views SpaceX not just as a rocket company, but a disruptive player in orbital edge computing and satellite internet, with a potential valuation up to $3.1 trillion. ARK highlights Starlink's shift from high cash burn to ultra-high gross margin profitability, projecting significant future revenue. Despite short-term volatility, Wood remains bullish on SpaceX's long-term growth driven by space-based data processing and energy infrastructure.

Latest articles

Opendoor volume surpasses short interest after Russell 3000 addition

Opendoor shares face Russell 3000 test after 4.5x volume spike

28 June 2026
Opendoor Technologies (NASDAQ:OPEN) surged 448% above average trading volume Friday as its Russell 3000 inclusion took effect, with 171.65 million shares traded—exceeding total short interest and equaling 21% of public float—while the stock closed up 1.63% at $4.37; analysts maintain a Hold consensus and see limited rally potential near current prices.
Coeur Mining shares eye index-driven moves after 8.5% weekly slide

Coeur Mining shares eye index-driven moves after 8.5% weekly slide

28 June 2026
Coeur Mining (NYSE:CDE) ended its first week in the S&P MidCap 400 down 8.5% from June 18, despite Friday’s massive $2.7 billion volume—about 16% of its market cap—highlighting investor caution after recent acquisitions and index changes, as the stock lagged silver-miner peers even with a record quarter expected.
Go toTop